CISH-knockout TILs (INT-CISH-TIL)

About Intima Bioscience

Intima Bioscience is pioneering a novel approach to cancer immunotherapy by targeting the intracellular checkpoint protein CISH (Cytokine-Inducible SH2-containing protein), a key negative regulator of T-cell signaling. The company has advanced into clinical trials, with a first-in-human study (NCT04426669) using CRISPR-Cas9 to genetically engineer CISH-knockout tumor-infiltrating lymphocytes (TILs) in patients with metastatic gastrointestinal cancers, with initial data presented in 2025. Beyond cell therapy, Intima is developing a small molecule inhibitor platform against CISH, aiming for an orally available, off-the-shelf therapeutic. Its strategy positions it at the intersection of cutting-edge gene editing and traditional drug discovery to overcome limitations of current checkpoint inhibitors.

Therapeutic Areas